Monte Rosa Therapeutics (GLUE) Other Operating Expenses (2022 - 2025)
Monte Rosa Therapeutics' (GLUE) quarterly Other Operating Expenses came in at $59000.0 in Q1 2025, up 145.83% quarter-over-quarter from $24000.0 in Q2 2023.
Monte Rosa Therapeutics (GLUE) Other Operating Expenses (2022 - 2025) Analysis & Trends
Monte Rosa Therapeutics' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $59000.0 for Q1 2025.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $59000.0 in Q1 2025; TTM through Dec 2025 was $59000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $59000.0, changed N/A from the prior year.
- Other Operating Expenses improved to $59000.0 in Q1 2025 per GLUE's latest filing, from $24000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $125000.0 in Q1 2022 and bottomed at -$16000.0 in Q3 2022.
- The 3-year median for Other Operating Expenses is $41500.0 (2023), against an average of $48000.0.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 59,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Sep 30, 2022 | -16,000.00 |
| Mar 31, 2022 | 125,000.00 |